World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 19 March 2012
Main ID:  EUCTR2006-006658-89-HU
Date of registration: 31/07/2008
Prospective Registration: No
Primary sponsor: Amgen Inc
Public title: A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Scientific title: A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Date of first enrolment: 17/06/2008
Target sample size: 184
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006658-89
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no  
Phase: 
Countries of recruitment
Belgium France Hungary Spain United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
Disease Related

• Histologically or cytologically confirmed non-small cell lung cancer. Mixed tumors will be categorized by the predominant cell type unless small cell elements are present in which case the subject will be ineligible. Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy.
• Subjects must have advanced non-small cell lung cancer defined as stage IIIB
with malignant pleural effusion or stage IV or recurrent disease (recurrent
disease is defined as documented disease progression following complete
surgical resection for stage I or II disease). Subjects with non-measurable but
evaluable disease can be included in the study
• Planning to receive up to 6 cycles of chemotherapy
• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

Demographic

• Men or women = 18 years of age

Ethical

• Before any study specific procedure is performed, the appropriate approved written
informed consent must be obtained

Laboratory

The following results must be obtained within 7 days before
enrollment/randomization unless indicated otherwise:
• Hematological function as follows:
- Hemoglobin = 9 g/dL
- Absolute neutrophil count = 1.5 x 109/L
- Platelet count = 100 x 109/L (without a transfusion = 14 days prior to enrollment or randomization)
• Renal function, as follows:
- Calculated creatinine clearance = 40 mL/minute
• Hepatic function, as follows:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 x ULN
OR AST or ALT = 5.0 x ULN if clearly attributable to liver metastasis
- Total bilirubin = 1.5 x ULN
- Alkaline phosphatase = 2.0 x ULN OR alkaline phosphatase = 5 x ULN if liver or bone metastases are present
• Partial thromboplastin (PTT) = 1.2 x ULN and international normalized ratio (INR)
= 1.5, unless subject is on anti-coagulation therapy. Subjects on therapeutic anticoagulation
are eligible if there is no bleeding and they are on a stable dose of
anticoagulation therapy (eg, on warfarin with an INR of 2 to 3) for at least 14 days
before enrollment/randomization
• Amylase = 2 x ULN
• Lipase = 2 x ULN

General
• Plan to begin protocol specific therapy = 7 days prior to enrollment/randomization
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Disease Related

• Untreated or symptomatic central nervous system metastases.
- Subjects with a history of CNS metastases that are both definitively
treated and stably controlled are eligible if all of the following apply:
1)definitive therapy has been administered (surgery and/or radiation
therapy); 2) there is no additional treatment planned for brain
metastases; 3) the subject is clinically stable; 4) the subject is off
corticosteroids or on a stable dose of corticosteroids for at least 14
days prior to enrollment/randomization•
• Prior chemotherapy as follows:
- Any prior chemotherapy for advanced non-small cell lung cancer
- Any prior adjuvant or neo-adjuvant chemotherapy for non-small cell lung
cancer = 52 weeks prior to enrollment/randomization. Adjuvant or neoadjuvant
chemotherapy completed > 52 weeks prior to randomization is
permitted.
- Any prior chemoradiation for non-small cell lung cancer.
• Central (chest) radiation therapy = 28 days prior to randomization, radiation therapy for peripheral lesions = 14 days prior to enrollment/randomization
• A history of other malignancies (except: curatively treated non-melanoma skin cancer, in-situ cancer of the cervix, or other in situ cancer with similarly favorable prognosis) unless treated with curative intent, with no treatment administered and without evidence of disease for = 3 years
• Other abnormal medical conditions
• Documented myocardial infarction or unstable/uncontrolled cardiac condition (eg,
unstable angina, congestive heart failure [New York Heart Association > Class II])
= 52 weeks prior to enrollment/randomization
• History of arterial thrombosis, pulmonary embolus, deep vein thrombosis or hemorrhagic disorders = 28 days prior to enrollment/randomization
• History of any medical or psychiatric condition or addictive disorder, or laboratory
abnormality that in the opinion of the investigator, may increase the risks associated with study participation or study treatments or may interfere with the conduct of the study or interpretation of study results
• Major surgical procedure = 30 days prior to enrollment/randomization or not yet
recovered from prior major surgery
• Minor surgical procedure = 7 days prior to enrollment/randomization or not yet recovered from prior minor surgery
• Known positive test for human immunodeficiency virus, hepatitis C virus or acute or
chronic hepatitis B infection
• Any co-morbid disease that would increase the risk of toxicity

Medications and other treatments

• Currently treated or previously treated with biologic, small molecule, immunotherapy, or other agents to treat advanced non-small cell lung cancer
• Recent infection requiring a course of systemic anti-infectives that was completed
= 7 days before enrollment/randomization (with the exception of uncomplicated urinary tract infection)
• Yellow fever vaccination within 30 days of randomization

General

• Subject is not able to tolerate intravenous drug infusions
• Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agent(s)
• Subject of child-bearing potential is evidently pregnant or is breast feeding
• Woman or man with partner of childbearing potential not consenting to use
adequate contraceptive precautions ie double barrier contraceptive methods (eg
diaphragm plus condom), or abstinence during the course of the study and for 3
months after the la


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Stage IIIb/IV Non-Small Cell Lung Cancer
MedDRA version: 9.1 Level: LLT Classification code 10029519 Term: Non-small cell lung cancer stage III
MedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IV
Intervention(s)

Product Name: AMG 655
Product Code: AMG 655
Pharmaceutical Form: Intravenous infusion
INN or Proposed INN: AMG 655
Current Sponsor code: AMG 655
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Intravenous infusion
Route of administration of the placebo: Intravenous use

Primary Outcome(s)
Main Objective: Part 1 (Phase 1b): To determine the maximum tolerated dose up to a
target dose of 15 mg/kg of AMG 655 that can be administered in
combination with paclitaxel/carboplatin

Part 2 (Phase 2): To estimate the efficacy of AMG 655 as assessed by progression free survival time (at two doses selected in part 1) in combination with paclitaxel/carboplatin
Primary end point(s): Part 1: The incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicities

Part 2: Progression free survival
Secondary Objective: Part 1:
To evaluate the safety and tolerability of escalating doses of AMG 655 in
combination with paclitaxel/carboplatin
To evaluate parameters of clinical benefit as measured by objective
response rate, duration of response, time-to-response, progression-free
survival and overall survival
To evaluate the pharmacokinetics of AMG 655
To evaluate anti-AMG 655 antibody formation

Part 2:
To estimate the clinical benefit of AMG 655 in combination with
paclitaxel/carboplatin as measured by overall objective response rate,
duration of response, time-to-response and overall survival
To evaluate the safety and tolerability of AMG 655 in combination with
paclitaxel/carboplatin
To evaluate the pharmacokinetics of AMG 655
To evaluate anti-AMG 655 antibody formation
Secondary Outcome(s)
Secondary ID(s)
2006-006658-89-BE
20060295
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history